Cartography Biosciences Advances Strategic Oncology Collaboration with Gilead’s First Option Target Exercise

Cartography Biosciences said Gilead has chosen to license a new cancer target discovered using its ATLAS and SUMMIT platforms. This is an important step in their partnership to develop more precise cancer treatments. Gilead will now handle development and sales, while Cartography earns payments and continues working on finding more targets.